698 related articles for article (PubMed ID: 29115895)
1. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H
Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis.
Saha S; Araf Y; Promon SK
J Egypt Natl Canc Inst; 2022 Feb; 34(1):8. PubMed ID: 35187602
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Chen M; Zhao H
Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
[TBL] [Abstract][Full Text] [Related]
6. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
Pomerantz T; Brooks R
Curr Treat Options Oncol; 2024 Apr; 25(4):510-522. PubMed ID: 38472567
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of circulating tumor DNA in metastatic cancers.
Raei N; Safaralizadeh R; Latifi-Navid S
Expert Rev Mol Diagn; 2023; 23(12):1209-1220. PubMed ID: 37797209
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
10. The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues.
Yang N; Li Y; Liu Z; Qin H; Du D; Cao X; Cao X; Li J; Li D; Jiang B; Duan L; Yang H; Zhang Z; Lin H; Li J; Yang Z; Xiong L; Shen H; Lin L; Li F
BMC Cancer; 2018 Mar; 18(1):319. PubMed ID: 29566644
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
12. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
Dhayat SA; Yang Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA analysis for tumor diagnosis.
Wang YH; Song Z; Hu XY; Wang HS
Talanta; 2021 Jun; 228():122220. PubMed ID: 33773726
[TBL] [Abstract][Full Text] [Related]
14. Interlaboratory assessment of droplet digital PCR for quantification of BRAF V600E mutation using a novel DNA reference material.
Dong L; Wang X; Wang S; Du M; Niu C; Yang J; Li L; Zhang G; Fu B; Gao Y; Wang J
Talanta; 2020 Jan; 207():120293. PubMed ID: 31594564
[TBL] [Abstract][Full Text] [Related]
15. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.
Myint NNM; Verma AM; Fernandez-Garcia D; Sarmah P; Tarpey PS; Al-Aqbi SS; Cai H; Trigg R; West K; Howells LM; Thomas A; Brown K; Guttery DS; Singh B; Pringle HJ; McDermott U; Shaw JA; Rufini A
Cell Death Dis; 2018 Aug; 9(9):894. PubMed ID: 30166531
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
18. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
[TBL] [Abstract][Full Text] [Related]
19. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
[TBL] [Abstract][Full Text] [Related]
20. From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis.
Peng R; Zhang R; Horan MP; Zhou L; Chai SY; Pillay N; Tay KH; Badrick T; Li J
Oncologist; 2020 Mar; 25(3):218-228. PubMed ID: 32162803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
